Clinical Trials Insight: 700044207

Trial Profile

Clinical Trials Insight: 700044207

Planning
Phase of Trial: Phase II

Latest Information Update: 14 May 2010

At a glance

  • Drugs Clavulanic acid (Primary)
  • Indications Erectile dysfunction; Male sexual dysfunction
  • Focus Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 14 May 2010 Preliminary data is expected to be available in 2011, according to a Rexahn Pharmaceuticals media release.
    • 08 Mar 2010 A phase IIb protocol for clavulanic acid [Zoraxel] for the treatment of erectile dysfunction has been submitted to the US FDA, according to a Rexahn media release.
    • 22 Feb 2010 A protocol is expected to be submitted to the US FDA for a phase IIb clinical trial in sexual dysfunction during the first half of 2010, according to a Rexahn media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top